Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
National Cancer Institute (NCI)
PRIMARY OBJECTIVES: I. To evaluate the safety and tolerability of camonsertib with concurrent head and neck stereotactic body radiotherapy (SBRT) reirradiation for patients with recurrent head and neck squamous cell carcinoma (HNSCC). II. To determine the recommended phase 2 dose (RP2D) of camonsertib in combination with concurrent SBRT in these patients. SECONDARY OBJECTIVES: I. To assess overall response rate within the radiation therapy field for patients treated with camonsertib and SBRT. II. To assess progression-free survival (PFS) with camonsertib and SBRT in patients with recurrent or new primary HNSCC within a previously irradiated field. EXPLORATORY OBJECTIVES: I. To identify predictive biomarkers of response to camonsertib and SBRT, including, but not limited to genetic alterations of ATM and TP53, human papillomavirus (HPV) status, tumor mutational load, and circulating tumor deoxyribonucleic acid (DNA). II. To characterize the pharmacokinetics (PK) of camonsertib. OUTLINE: This is a dose-escalation study of camonsertib in combination with SBRT followed by a dose-expansion study. Patients undergo 4 or 5 treatment fractions of SBRT twice weekly, 2-3 days apart between fractions, over 3 weeks. Patients receive camonsertib orally (PO) once daily (QD) on the day of and the day after each radiation therapy treatment. Patients also undergo positron emission tomography (PET)/computed tomography (CT) or CT and collection of blood samples throughout the trial. After completion of study treatment, patients are followed up at weeks 4, 5, 6, 7, 16, 29, 42, and 55.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
